CN101456886B - Use of daphne primeverose-genkwanin and daphne plant - Google Patents
Use of daphne primeverose-genkwanin and daphne plant Download PDFInfo
- Publication number
- CN101456886B CN101456886B CN2007101719939A CN200710171993A CN101456886B CN 101456886 B CN101456886 B CN 101456886B CN 2007101719939 A CN2007101719939 A CN 2007101719939A CN 200710171993 A CN200710171993 A CN 200710171993A CN 101456886 B CN101456886 B CN 101456886B
- Authority
- CN
- China
- Prior art keywords
- daphne
- dpg
- purposes
- formula
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
The invention discloses a Daphne primeverosyl-Genkwanine (DPG) of a formula I , or an alcohol extract of Daphne plants containing DPG of the formula I, or application of the Daphne plants containing DPG of the formula I to the preparation of medicines treating leukemia. The invention also provides a medicine composite containing DPG shown by the formula I.
Description
Technical field
The present invention relates to the medicinal plants field.The purposes of the DPG (Daphneprimeverosyl-Genkwanine, DPG) that relates more specifically to daphne plant and from daphne plant, extract.
Background technology
Development and progress along with medical science, leukemic treatment level has also had large increase, people not only are satisfied with patient's fully alleviation, and be devoted to finally to make the research of the long-term anosis survival of patient and even recovery from illness, present leukemic methods for the treatment of has chemotherapy, therapy of combing traditional Chinese and Western medicine and hematopoietic stem cell transplantation etc.
Chemotherapy is to use chemicals to kill the leukemia cell, makes patient reach the purpose of long-term surviving and even healing.Leukemic type is a lot, should select different chemotherapy regimens to different type of leukemia.At present, the success ratio of chemotherapy is lower, and failed reason has the chemotherapy stage internal cause to infect and the hemorrhage Deaths that causes, or leukemia cell's resistance and to no effect.
For therapy of combing traditional Chinese and Western medicine, no matter be simple traditional Chinese medical herbal treatment, or Chinese and western medical unite use, effect is not very good.
Hematopoietic stem cell transplantation (HSCT) can be described as a leukemic method of the most basic treatment.But there is very large risk in it, mainly contain 2 points: have many transplanting related complications among the one, the HSCT, still have the leukemia relapse problem behind the 2nd, the HSCT: main transplanting related complication has: HVOD, its sickness rate is 25%, mortality ratio is 80%, graft versus host disease (GVH disease), sickness rate 10%-80%.The leukemia relapse rate is approximately 15%-50% behind the HSCT.
Therefore, this area is in the urgent need to providing a kind of material and the method that can effectively treat the clone such as leukemia property malignant hematologic disease.
Summary of the invention
The present invention aims to provide the compound suc as formula I, or contains the plant milk extract of formula I compound, or contains the new purposes of the crude drug of formula I compound.
Second purpose of the present invention provides a kind of pharmaceutical composition.
The 3rd purpose of the present invention provides a kind of leukemic method for the treatment of.
In a first aspect of the present invention, provide a kind of suc as formula (the Daphne primeverosyl-Genkwanine of the DPG shown in the I, DPG), or contain alcohol extract suc as formula the daphne plant of the DPG shown in the I, or the daphne plant medicinal material that contains suc as formula the DPG shown in the I is preparing the purposes for the treatment of in the leukemic medicine
In another preference, described leukemia is selected from the resistance acute leukemia, chronic myelocytic leukemia, myelodysplastic syndrome (MDS), or whole multiple myeloma in latter stage (Kahler ' s disease).
In another preference, described daphne plant is selected from VC.Aureomariginatn (Daphne odora Thunb), lilac daphne (Daphne genkwaSieb.et Zucc), Bai Ruixiang (Daphne papyracea Wall.ex Steud), or Yunnan winter daphne (Daphne yunnanensis H.F.Zhou); The more preferably herb powder of daphne plant.
In another preference, described alcohol extract is selected from methyl alcohol or ethanol extraction.
In another preference, described alcohol extract is obtained by following step:
(a) daphne plant herb powder is obtained with methyl alcohol and/or extraction using alcohol.
In another preference, after step (a), also comprise step:
(b) alcohol extract that step (a) is obtained with chloroform soak, the centrifugal thing that is precipitated; With
(c) throw out is obtained alcohol extract after with water rinse.
In another preference, described medicine is for being selected from oral capsule, pulvis, tablet, tincture, patch, paste, decoction of medicinal ingredients, injection, sustained release dosage, medicinal liquor, or the formulation of oral liquid.
In a second aspect of the present invention, a kind of pharmaceutical composition is provided, it contains:
(i) as activeconstituents suc as formula the DPG (Daphneprimeverosyl-Genkwanine shown in the I, DPG), or contain alcohol extract suc as formula the daphne plant of the DPG shown in the I, or contain the daphne plant medicinal material suc as formula the DPG shown in the I; With
(ii) pharmaceutically acceptable carrier.
In another preference, the weight of described activeconstituents is to occupy the 1-99% of composition total weight.
In another preference, described daphne plant is selected from VC.Aureomariginatn (Daphne odora Thunb), lilac daphne (Daphne genkwaSieb.et Zucc), Bai Ruixiang (Daphne papyracea Wall.ex Steud), or Yunnan winter daphne (Daphne yunnanensis H.F.Zhou); Described alcohol extract is selected from methyl alcohol or ethanol extraction.
In a third aspect of the present invention, a kind of method for the treatment of leukemic medicine for preparing is provided, it comprises step: will be suc as formula (the Daphne primeverosyl-Genkwanine of the DPG shown in the I, DPG), or contain alcohol extract suc as formula the daphne plant of the DPG shown in the I, or the daphne plant medicinal material and the pharmaceutically acceptable carrier that contain suc as formula the DPG shown in the I are mixed to get.
In a fourth aspect of the present invention, a kind of leukemic method for the treatment of is provided, described method is that the patient is used suc as formula the DPG (Daphneprimeverosyl-Genkwanine shown in the I, DPG), or contain alcohol extract suc as formula the daphne plant of the DPG shown in the I, or contain the daphne plant medicinal material suc as formula the DPG shown in the I.
Accordingly, the invention provides a kind of material and the method that can effectively treat the clone such as leukemia property malignant hematologic disease.
Fig. 1 has shown the situation of L1210 L-1210.
Fig. 2 has shown the impact of DPG on the L1210 L-1210.
Fig. 3 has shown the situation of people's embryo normal fibroblast (HLF).
Fig. 4 has shown the impact of DPG on the normal protofibril cell of people's embryo (HLF).
Embodiment
The contriver is through extensive and deep research, and the herb that is surprised to find that daphne plant has positive effect on the pathology to human malignant's hemopathy.Further, the contriver finds to extract from above-mentioned daphne plant to obtain a kind of chemical structural formula suc as formula compound (the 5-0-β-OH-primeverose-genkwanin of I, Daphne primeverosyl-Genkwanine, DPG), it has obvious antiproliferative and apoptosis-promoting effect to the leukemia cell, can suppress leukemia cell's growth.
As used herein, " herb " refers to the herb of daphne plant, the root, stem, branch, the leaf that comprise plant, the preferred VC.Aureomariginatn of described daphne plant (Daphne odora Thunb), lilac daphne (Daphne genkwaSieb.et Zucc), Bai Ruixiang (Daphne papyracea Wall.ex Steud), or Yunnan winter daphne (Daphne yunnanensis H.F.Zhou).
As used herein, " herb powder " or " herb pulvis " is used interchangeably, refer to that herb with daphne plant dries after, be ground into 50-200 purpose particulate matter, preferred 70-150 order, more preferably 90-120 order.
As used herein, described " daphne plant medicinal material " can be the complete stool of daphne plant, also can be the part of described plant, such as root, stem, branch, leaf, flower and/or fruit etc.
Daphne plant herb powder provided by the invention can be used for treating leukemia, and using method is oral 3 times of every day, each 2 doses/50kg body weight, every dose 1 gram, every daily amount 6 grams.The doctor can do corresponding the adjustment according to disease and patient's particular case.
The invention provides the extract of daphne plant, described extract is selected from methyl alcohol or ethanol extraction.Can use the method for this area routine to obtain, a kind of preferred method is to add ethanol in the herb powder, refluxing extraction, centrifugal after, get alcohol extraction liquid, decompressing and extracting obtains pressed powder.A kind of better method is to add ethanol in the herb powder, refluxing extraction, centrifugal after, get alcohol extraction liquid, decompressing and extracting obtains pressed powder; Add chloroform, soaked overnight, next day is centrifugal, discards chloroform; Add again the chloroform washing once, the centrifuging and taking throw out; The decompressing and extracting chloroform obtains solid, and with distilled water rinsing twice, oven dry obtains refining extract (DPG).
Alcohol extract provided by the invention and/or DPG can be used for treating leukemia, and using method is every day 3 times, each 2 doses/50kg body weight, every dose of 10 milligrams of alcohol extract or DPG, 60 milligrams of every daily amounts.The doctor can do corresponding the adjustment according to disease and patient's particular case.
The leukemia that the present invention treats comprises the resistance acute leukemia, chronic myelocytic leukemia, myelodysplastic syndrome and whole multiple myeloma in latter stage (Kahler ' s disease).
Natural daphne plant of the present invention belongs to thymelaeceae, Myrtales, approximately 70 kinds, be distributed in Europe, north African and temperate zone, Asia and subtropical zone to Oceania, China has 35 kinds, and large section produces the west and south and the northwestward, the elsewhere is rare, and the phloem fiber of some kind is the raw material of paper processed, and some is for viewing and admiring.
Affiliated section thymelaeceae is as follows in China's principal item kind name:
Cusp winter daphne Daphne acutiloba Rehd.
Orange winter daphne Daphne auran thiaca Diels
Hide eastern winter daphne Daphne bholua Buch.-Ham.ex D.Don
Short tube winter daphne Daphne brevituba H.F.Zhou
Leaflet winter daphne Daphne championii Benth.
Spend less winter daphne Daphne depauperata H.F.Zhou
Daphne emeiensis Daphne emeiensis C.Y.Chang
Daphne erosiloba Daphne erosiloba C.Y.Chang
White arteries and veins winter daphne Daphne esquirolii Levl.
Short lobe winter daphne Daphne feddei Levl.
West, river winter daphne Daphne gemmata E.Pritz.
Lilac daphne Daphne genkwa Sieb.et Zucc.
Thin,tough silk hair winter daphne Daphne holosericea (Diels) Hamaya
Leishan winter daphne Daphne leishanensis H.F.Zhou
Long lobe winter daphne Daphnelongilobata (Lecomte) Turrill
Da Hua winter daphne Daphne macrantha Ludlow
Thin leaf winter daphne Daphne modesta Rehd.
Long stalk winter daphne Daphne pedunculata H.F. Zhou
Pale reddish brown winter daphne Daphne purpurascens S.C.Huang
Retuseleaf daphne bark Daphne retusa Hemsl.
Beak fruit winter daphne Daphne rhynchocarpa C.Y.Chang
Daphne tangutica Daphne tangu tica Maxim.
Thin flower winter daphne Daphne tenuiflora Bur.
Kowloon winter daphne Daphne tripartite H.F. Zhou
Xichou winter daphne Daphne xichouensis H.F. Zhou
The preferred kind of the present invention is VC.Aureomariginatn (Daphne odora Thunb), lilac daphne (DaphnegenkwaSieb.et Zucc), Bai Ruixiang (Daphne papyracea Wall.ex Steud), or Yunnan winter daphne (Daphne yunnanensis H.F. Zhou).
The above-mentioned feature that the present invention mentions, or the feature that embodiment mentions can arbitrary combination.All features that this case specification sheets discloses can with any composition forms and usefulness, each feature that discloses in the specification sheets can anyly provide the alternative characteristics of identical, impartial or similar purpose to replace.Therefore except special instruction is arranged, the feature that discloses only is the general example of equalization or similar features.
Major advantage of the present invention is:
1, the leukemic method reversible for the treatment of provided by the invention prolongs or stops leukemic recurrence;
2, the leukemic method for the treatment of provided by the invention can prevent multi-medicine drug resistance of leukaemia;
3, the leukemic method toxic side effect for the treatment of provided by the invention is little.
4, the method for the treatment of multiple myeloma provided by the present invention not only can lure into and obtain alleviation, and analgesic effect is obvious.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used for explanation the present invention and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example is usually according to normal condition or the condition of advising according to manufacturer.Unless otherwise indicated, otherwise all per-cent and umber by weight.
Unless otherwise defined, the same meaning that employed all specialties and scientific words and one skilled in the art are familiar with in the literary composition.In addition, any method similar or impartial to described content and material all can be applicable in the inventive method.The usefulness that better implementation method described in the literary composition and material only present a demonstration.
Embodiment 1
Preparation herb powder I
Adopt VC.Aureomariginatn Daphne odora Thunb herb, after drying, through being ground into 100 order particulate matter, obtain herb powder I.
Embodiment 2
Preparation herb powder II
Adopt lilac daphne Daphne genkwa Sieb.et Zucc herb, after drying, through being ground into 100 order particulate matter, obtain herb powder II.
Embodiment 3
Preparation herb powder III
Adopt white winter daphne Daphne papyracea Wall.ex Steud. herb, after drying, through being ground into 100 order particulate matter, obtain herb powder III.
Preparation herb powder IV
Adopt Yunnan winter daphne Daphne yunnanensis H.F.Zhou, after drying, through being ground into 100 order particulate matter, obtain herb powder IV.
Embodiment 5
Preparation alcohol extract I
Take by weighing 50 gram herb powder I, add 200 milliliters of ethanol, refluxing extraction 2 hours.Centrifugal, get alcohol extraction liquid, decompressing and extracting, obtaining pressed powder is alcohol extract I.
Embodiment 6
Preparation alcohol extract II
Take by weighing 50 gram herb powder II, add 200 ml methanol, refluxing extraction 2 hours.Centrifugal, get methanol extraction liquid, decompressing and extracting, obtaining pressed powder is alcohol extract II.
Embodiment 7
Preparation alcohol extract III
Take by weighing 50 gram herb powder III, add 200 ml methanol, refluxing extraction 2 hours.Centrifugal, get methanol extraction liquid, decompressing and extracting, obtaining pressed powder is alcohol extract III.
Embodiment 8
Preparation alcohol extract IV
Take by weighing 50 gram herb powder IV, add 200 milliliters of ethanol, refluxing extraction 2 hours.Centrifugal, get alcohol extraction liquid, decompressing and extracting, obtaining pressed powder is alcohol extract IV.
Embodiment 9
Preparation DPG (No.1)
Take by weighing 50 gram herb powder I, add 200 milliliters of ethanol, refluxing extraction 2 hours.Centrifugal, get alcohol extraction liquid, decompressing and extracting, obtaining pressed powder is alcohol extract I.
Add 50 milliliters of chloroforms, soaked overnight.Next day is centrifugal, discards chloroform; Add again 20 milliliters of chloroform washings once, the centrifuging and taking throw out.The decompressing and extracting chloroform obtains solid, and with distilled water rinsing twice, oven dry obtains refining extract (DPG (No.1)).
Embodiment 10
Preparation DPG (No.2)
Take by weighing 50 gram herb powder II, add 200 ml methanol, refluxing extraction 2 hours.Centrifugal, get methanol extraction liquid, decompressing and extracting, obtaining pressed powder is alcohol extract II.
Add 50 milliliters of chloroforms, soaked overnight.Next day is centrifugal, discards chloroform; Add again 20 milliliters of chloroform washings once, the centrifuging and taking throw out.The decompressing and extracting chloroform obtains solid, and with distilled water rinsing twice, oven dry obtains refining extract (DPG (No.2)).
Embodiment 11
Preparation DPG (No.3)
Take by weighing 50 gram herb powder III, add 200 ml methanol, refluxing extraction 2 hours.Centrifugal, get methanol extraction liquid, decompressing and extracting, obtaining pressed powder is alcohol extract III.
Add 50 milliliters of chloroforms, soaked overnight.Next day is centrifugal, discards chloroform; Add again 20 milliliters of chloroform washings once, the centrifuging and taking throw out.The decompressing and extracting chloroform obtains solid, and with distilled water rinsing twice, oven dry obtains refining extract (DPG (No.3)).
Embodiment 12
Preparation DPG (No.4)
Take by weighing 50 gram herb powder IV, add 200 milliliters of ethanol, refluxing extraction 2 hours.Centrifugal, get alcohol extraction liquid, decompressing and extracting, obtaining pressed powder is alcohol extract IV.
Add 50 milliliters of chloroforms, soaked overnight.Next day is centrifugal, discards chloroform; Add again 20 milliliters of chloroform washings once, the centrifuging and taking throw out.The decompressing and extracting chloroform obtains solid, and with distilled water rinsing twice, oven dry obtains refining extract (DPG (No.3)).
Embodiment 13
The evaluation of effective constituent
Standard substance DPG is available from SIGMA, adopts the DPG highly finished product of the winter daphne plant extract of but same genus not of the same race from 4, and namely the DPG (No.1-4) that makes of embodiment 9-12 carries out the thin plate chromatographic analysis.
The actual conditions of thin plate chromatography:
The silica gel G plate, behind the point sample, chromatographic solution: propyl carbinol: acetic acid: water=4: 1: 1.
Find that the chromatography spot is unicity, and migration position is consistent with reference substance, molecular weight and reference substance are in full accord.
Chemistry analysis: the DPG highly finished product of the winter daphne plant extract of the not of the same race but same genus of standard substance and 4, it is DPG (No.1-4) contrast that embodiment 9-12 makes, all be particulate needle crystal powder, be insoluble to ether, chloroform or water, but be dissolved in methyl alcohol or ethanol.Character is identical.
Embodiment 14
The clinical pharmacology preliminary observation
Herb pulvis I treatment Chronic Myelogenous Leukemia patient (volunteer) 2 examples of using embodiment 1 to make, an example is invalid, and another example obtains partial rcsponse.The myeloid leukemia initiating cell is down to 7.5% from 18%.Medication at that time is: oral herb pulvis I, and each 1g, every day 3 times, being used in conjunction 14 days was 1 course for the treatment of.
The herb pulvis I that makes with embodiment 1 treats respectively refractory and recurrent acute leukemia 3 examples (ALL2 example, AGL1 example) (volunteer), and interior 1 routine AGL obtains partial rcsponse; 1 routine ALL takes a turn for the better, and 1 routine ALL is invalid.
The result shows, winter daphne herb pulvis has demonstrated has positive effect on the pathology to human malignant's hemopathy, after resistance acute leukemia and chronic myelocytic leukemia are taken antigen beginning cytological effect is arranged, and the leukemia cell obviously reduces, blood picture improves, and obtains partially or completely to alleviate.
Not only can pain relieving to multiple myeloma in whole latter stage (Kahler ' s sick), and blood picture improves, and Ig mono-clonal paraprotein descends.
Embodiment 15
The effect of alcohol extract
Adopt the alcohol extract I of embodiment 5 preparations to carry out test cell line, observe the external biological effect to the L1210 L-1210.Find significantly apoptosis-promoting effect of alcohol extract I, can suppress leukemia cell's growth.
Simultaneously, also adopt HLF (the normal protofibril cell of people's embryo) to test, find that alcohol extract I is to normal cell unrestraint effect.
Embodiment 16-18
The effect of alcohol extract
Repeat test cell line among the embodiment 15 with the alcohol extract II-IV of embodiment 6-8 preparation, find that equally alcohol extract II-IV has obvious apoptosis-promoting effect, can suppress leukemia cell's growth, and for normal cell without impact.
Embodiment 19
The effect of DPG
Adopt the DPG (No.1) of embodiment 9 preparations to carry out test cell line, observe the external biological effect to the L1210 L-1210.
Wherein Fig. 1 is contrast: do not add DPG, cultivated 3 days for 37 ℃;
Fig. 2 cultivated 3 days for 37 ℃ for adding 2ug/ml DPG.
Find significantly apoptosis-promoting effect of DPG, can suppress leukemia cell's growth.
Simultaneously, also adopt HLF (people's embryo normal fibroblast) to test, find that DPG is to normal cell unrestraint effect (Fig. 3,4).
Adopt DPG (No.1) the treatment multiple myeloma in whole latter stage of embodiment 9 preparations, the myeloma cell is down to 4.5% from 37%.Medication is: oral full DPG (No.1), each 10 milligrams, every day 3 times, being used in conjunction 14 days was 1 course for the treatment of.It is normal that Ig mono-clonal paraprotein (M-albumen) recovers, and only ostalgia is obvious.
Embodiment 20-22
The effect of DPG
The cell in vitro that the DPG (No.2-4) that embodiment 10-12 is prepared repeats among the embodiment 19 is tested, the result shows, the DPG highly finished product DPG (No.1-4) of the winter daphne plant extract of standard substance but same genus not of the same race with 4 has the effect of identical inhibition leukemia growth, and Dosages is consistent.
Embodiment 23
Preliminary toxicologic study
The big white mouse sub-acute toxicity test
Get herb pulvis I, the feeding white mouse, dosage is 0.5mg/kg/ days, serve on 15 days, proves nontoxicity.DPG (No.1) feeding white mouse, dosage is 0.5mg/kg/ days, serve on 15 days, proves equally nontoxicity.
The small white mouse acute toxicity test
Get high density suspension (herb pulvis I), dosage is the same, takes, proves nontoxicity for 1 time.DPG (No.1) feeding white mouse, dosage is 0.5mg/kg/ days, serve on 15 days, proves equally nontoxicity.
In above rat experiment, prove that also have no obvious acute toxicity test every day thousands of times of dosage that winter daphne herb pulvis single dose surpasses clinical use.
Embodiment 24-26
Preliminary toxicologic study
The herb pulvis II-IV for preparing with embodiment 2-4 and embodiment 10-12 and DPG (No.2-4) repeat the test of embodiment 23, and the result is similar.
Embodiment 27
Pharmaceutical composition
Prescription one:
Herb pulvis I1 gram
Curcumine 0.2 gram
Excipient 0.3 gram
Being pressed into tablet makes
Prescription two:
100 milligrams of alcohol extract I
Curcumine 0.2 gram
Excipient 0.3 gram
Being pressed into tablet makes
Prescription three:
100 milligrams of alcohol extract III
Artemisinin 0.2 gram
Excipient 0.3 gram
Being pressed into tablet makes
Prescription four:
10 milligrams of DPG (No.2)
Artemisinin 0.2 gram
Excipient 0.3 gram
Being pressed into tablet makes
Prescription five:
10 milligrams of DPG (No.3)
Be dissolved in 150 microlitre Virahols (solubility promoter)
2 milliliters of injection waters
Filtration sterilization obtains injection
Above prescription is given about 10 and is suffered from the resistance acute leukemia, chronic myelocytic leukemia, and after the volunteer of MDS and Kahler ' s disease used, the state of an illness all was improved.
All quote in this application as a reference at all documents that the present invention mentions, just as each piece document is quoted separately as a reference.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims limited range equally.
Claims (12)
1. one kind suc as formula the DPG shown in the I, or contain alcohol extract suc as formula the daphne plant of the DPG shown in the I, or contain suc as formula the daphne plant medicinal material of the DPG shown in the I purposes in the medicine of preparation treatment myelodysplastic syndrome or multiple myeloma
2. purposes as claimed in claim 1 is characterized in that, described multiple myeloma is multiple myeloma in latter stage at end.
3. purposes as claimed in claim 1 is characterized in that, described daphne plant is selected from VC.Aureomariginatn, lilac daphne, white winter daphne, or Yunnan winter daphne.
4. such as claim 1 or 3 described purposes, it is characterized in that, described daphne plant is the herb powder of daphne plant.
5. purposes as claimed in claim 1 is characterized in that, described alcohol extract is selected from ethanol extraction.
6. purposes as claimed in claim 1 is characterized in that, described alcohol extract is obtained by following step:
(a) daphne plant herb powder is obtained with extraction using alcohol.
7. purposes as claimed in claim 6 is characterized in that, also comprises step after step (a):
(b) alcohol extract that step (a) is obtained with chloroform soak, the centrifugal thing that is precipitated; With
(c) throw out is obtained alcohol extract after with water rinse.
8. purposes as claimed in claim 1 is characterized in that, described medicine is for being selected from oral capsule, pulvis, tablet, tincture, patch, paste, decoction of medicinal ingredients, injection, sustained release dosage, medicinal liquor, or the formulation of oral liquid.
9. purposes as claimed in claim 1 is characterized in that, described medicine is a kind of pharmaceutical composition, and described pharmaceutical composition contains:
(i) as activeconstituents suc as formula the DPG shown in the I, or contain alcohol extract suc as formula the daphne plant of the DPG shown in the I, or contain the daphne plant medicinal material suc as formula the DPG shown in the I; With
(ii) pharmaceutically acceptable carrier.
10. purposes as claimed in claim 9 is characterized in that, the weight of described activeconstituents is to occupy the 1-99% of composition total weight.
11. purposes as claimed in claim 9 is characterized in that, described daphne plant is selected from VC.Aureomariginatn, lilac daphne, white winter daphne, or Yunnan winter daphne; Described alcohol extract is selected from methyl alcohol or ethanol extraction.
12. purposes as claimed in claim 1, it is characterized in that, described medicine prepares by the following method, described method comprises step: will be suc as formula the DPG shown in the I, or contain alcohol extract suc as formula the daphne plant of the DPG shown in the I, or the daphne plant medicinal material and the pharmaceutically acceptable carrier that contain suc as formula the DPG shown in the I mix.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101719939A CN101456886B (en) | 2007-12-10 | 2007-12-10 | Use of daphne primeverose-genkwanin and daphne plant |
| PCT/CN2008/073216 WO2009074065A1 (en) | 2007-12-10 | 2008-11-27 | Use of daphne primeverose genkwanine and daphne plants |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101719939A CN101456886B (en) | 2007-12-10 | 2007-12-10 | Use of daphne primeverose-genkwanin and daphne plant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101456886A CN101456886A (en) | 2009-06-17 |
| CN101456886B true CN101456886B (en) | 2013-04-10 |
Family
ID=40755234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101719939A Expired - Fee Related CN101456886B (en) | 2007-12-10 | 2007-12-10 | Use of daphne primeverose-genkwanin and daphne plant |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101456886B (en) |
| WO (1) | WO2009074065A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110301102A1 (en) * | 2010-06-07 | 2011-12-08 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
| CN113274438A (en) * | 2021-05-24 | 2021-08-20 | 上海交通大学 | Preparation and application of lilac daphne flower bud extract |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2597751A1 (en) * | 1986-04-24 | 1987-10-30 | Ragot Jacqueline | Synergistic effect between two molecules of plant origin, namely senegenin and 5-O- beta -D-primeverosylgenkwanin, which may be used in the treatment of disorders associated with immune imbalances |
| CN1950390A (en) * | 2004-03-11 | 2007-04-18 | 迈克尔·普罗斯特 | Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same |
-
2007
- 2007-12-10 CN CN2007101719939A patent/CN101456886B/en not_active Expired - Fee Related
-
2008
- 2008-11-27 WO PCT/CN2008/073216 patent/WO2009074065A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2597751A1 (en) * | 1986-04-24 | 1987-10-30 | Ragot Jacqueline | Synergistic effect between two molecules of plant origin, namely senegenin and 5-O- beta -D-primeverosylgenkwanin, which may be used in the treatment of disorders associated with immune imbalances |
| CN1950390A (en) * | 2004-03-11 | 2007-04-18 | 迈克尔·普罗斯特 | Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same |
Non-Patent Citations (2)
| Title |
|---|
| 张薇等.毛瑞香酚性成分研究.《天然产物研究与开发》.2005,第17卷(第1期),26-28. * |
| 李玲芝等.芫花的化学成分及药理作用研究进展.《沈阳药科大学学报》.2007,第24卷(第9期),587-592. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101456886A (en) | 2009-06-17 |
| WO2009074065A1 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Wyk et al. | A review of the taxonomy, ethnobotany, chemistry and pharmacology of Sutherlandia frutescens (Fabaceae) | |
| CN101411761B (en) | Novel use of plants in sorbus malus group of malus | |
| CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
| CN102309655B (en) | Traditional Chinese medicine composition with effect of preventing and treating cancers and application of Chinese medicinal composition | |
| Wen et al. | A comprehensive review of Rubia cordifolia L.: Traditional uses, phytochemistry, pharmacological activities, and clinical applications | |
| CN101978987A (en) | Application of herba rabdosiae rubescentis extract to preparation of medicament for treating and resisting cerebral ischemia | |
| CN101456886B (en) | Use of daphne primeverose-genkwanin and daphne plant | |
| CN100571761C (en) | A kind of Chinese medicine composition and preparation method for the treatment of hepatopathy | |
| KR0160108B1 (en) | Anticancer agent of raw ingredient extracted from the tree named gleditschia officinalis | |
| Umakrithika | A comprehensive overview of plant genus: Lindernia | |
| CN102688263B (en) | Geranium strictipes effective part preparation and medical use of geranium strictipes for preventing and curing colonitis | |
| CN112245499B (en) | Chinese patent medicine for treating lumbar intervertebral disc protrusion, preparation method and application | |
| CN102309656B (en) | Traditional Chinese medicine composition with effect of preventing and treating cancers and medicinal application of traditional Chinese medicine composition | |
| CN105687274B (en) | New application of acanthopanax giraldii harms wood heart or extract thereof | |
| CN102961440B (en) | Pharmaceutical composition containing cyclooxygenase and natural doxorubicin or doxorubicin-like substances, its preparation method and application in preparation of multiple drugs | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN102114065B (en) | Longhairy antenoron herb and common threewingnut root Chinese medicinal composition with effect of preventing and treating cancer and application thereof | |
| CN100427099C (en) | Juglans mandshurica maxim pdysaccharide preparation capable of effectively treating brain cancer and its preapring method | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| Ydyrys | An Overview of Medical Uses and Chemical Composition of Arctium tomentosum mill. | |
| CN104083690B (en) | Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing breast cancer | |
| CN102429951B (en) | Flavone-saponin extract of humifuse euphorbia herb and application thereof | |
| Akinfenwa et al. | Helichrysum Genus and Compound Activities in the Management of Diabetes Mellitus. Plants 2022, 11, 1386 | |
| CN105641148A (en) | Application of bitter orange volatile oil extract in preparation of antidepressant drug | |
| CN105535070A (en) | Medicine composition for treating diabetes and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130410 Termination date: 20191210 |